184 citations,
February 2015 in “EBioMedicine” A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.
182 citations,
December 2017 in “Journal of the American Academy of Dermatology” Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.
157 citations,
December 2015 in “Journal of the American Academy of Dermatology” A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.
130 citations,
February 2018 in “Journal of Investigative Dermatology” Tofacitinib may help treat severe hair loss, but more research is needed.
124 citations,
October 2019 in “Frontiers in Immunology” Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
88 citations,
August 2019 in “Frontiers in immunology” Tyrosine kinases are important in skin autoimmune diseases and could be targets for new treatments.
82 citations,
March 2016 in “Autoimmunity reviews” Animal models have helped understand hair loss from alopecia areata and find new treatments.
77 citations,
June 2017 in “Advances in Therapy” New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.
70 citations,
October 2020 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Janus kinase inhibitors are promising drugs for treating autoimmune and inflammatory diseases.
66 citations,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
53 citations,
July 2018 in “Drug design, development and therapy” Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.
50 citations,
May 2021 in “Frontiers in immunology” Certain immune cells contribute to skin autoimmune diseases, and some treatments can reverse hair loss in these conditions.
49 citations,
March 2017 in “Journal of the American Academy of Dermatology” Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
48 citations,
November 2017 in “Journal of the American Academy of Dermatology” Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
46 citations,
October 2018 in “JCI insight” CD8+ T cells are involved in alopecia areata and may cause disease relapse.
40 citations,
September 2018 in “Journal of the American Academy of Dermatology” Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.
37 citations,
January 2016 in “Drug design, development and therapy” Tofacitinib citrate is effective for moderate-to-severe chronic plaque psoriasis but has safety concerns at higher doses.
37 citations,
October 2017 in “Clinical and Experimental Dermatology” Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
36 citations,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
27 citations,
January 2020 in “Experimental Dermatology” Immune cells affect hair growth and could lead to new hair loss treatments.
26 citations,
January 2019 in “Expert Opinion on Investigational Drugs” New treatments for hair loss show promise, but more research is needed to confirm their safety and effectiveness.
26 citations,
October 2016 in “American journal of clinical dermatology” New treatments like JAK inhibitors show promise for reversing alopecia areata.
25 citations,
December 2017 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” Targeted cytokine treatments may help with alopecia areata, but more research is needed.
24 citations,
June 2016 in “Acta dermato-venereologica” Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.
23 citations,
September 2017 in “Journal of the American Academy of Dermatology” Apremilast did not work for treating severe alopecia areata.
22 citations,
September 2017 in “Skin appendage disorders” Ruxolitinib helped a man regrow his beard after years of hair loss.
21 citations,
May 2017 in “Paediatric drugs” Individualized treatment plans are crucial for children with alopecia areata, with promising options like JAK inhibitors showing significant hair regrowth.
21 citations,
November 2015 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” There is no cure for alopecia areata, but treatments like JAK inhibitors show promise.
15 citations,
January 2023 in “Antioxidants” Oxidative stress plays a significant role in alopecia areata, and new treatments may include JAK inhibitors and antioxidants.
15 citations,
January 2022 in “Immune Network/Immune network” New targeted immunotherapies are improving treatment for inflammatory skin diseases.